<unk>  is administered in several forms: tablets, subcutaneous injection, and nasal spray. Oral administration (as the succinate salt) suffers from poor bioavailability, partly due to presystemic metabolism—some of it gets broken down in the stomach and bloodstream before it reaches the target arteries. A new rapid-release tablet formulation has the same bioavailability, but the maximum concentration is achieved on average 10–15 minutes earlier. When injected,<unk>  is faster-acting (usually within 10 minutes), but the effect lasts for a shorter time.<unk>  is metabolised primarily by monoamine oxidase A into 2-{5-(methylsulfamoyl)methyl-indole-3-yl}acetic acid, which is then conjugated to glucuronic acid. These metabolites are excreted in the urine and bile. Only about 3% of the active drug may be recovered unchanged. There is no simple, direct relationship between<unk>  concentration (pharmacokinetics) per se in the blood and its anti-migraine effect (pharmacodynamics). This paradox has, to some extent, been resolved by comparing the rates of absorption of the various<unk>  formulations, rather than the absolute amounts of drug that they deliver.
Sumatriptan
Eletriptan
Frovatriptan
Rizatriptan
Almotriptan
Naratriptan
Triptan
Zolmitriptan